ABBV

AbbVie Inc. is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in therapeutic categories, including immunology, which include Humira, Skyrizi and Rinvoq; oncology, which include Imbruvica, Venclexta/Venclyxto, Epkinly and Elahere; aesthetics products, which include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience, which include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy and Qulipta; eye care, which consists of Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. It offers NX-13, a first-in-class, oral NLRX1 agonist, for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). It also offers CEL383, a first-in-class anti-TREM1 antibody, for the treatment of inflammatory bowel disease.